All In Biotech

Drug Trial Radar · NCT00035451

Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.

Last checked: Nov 19, 2026Latest source record: Oct 3, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 658 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

658

Actual

Start

Feb 2001

Primary completion

Jun 2003

Study completion Jun 2003

Sponsor

Lead sponsor
Forest LaboratoriesAbbVie (ABBV)
Sponsor type
Industry
First posted
May 6, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Atrial fibrillation (abnormal rhythm in the upper chamber of the heart) is a common supraventricular arrhythmia (a type of abnormal heart rhythm) for which antiarrhythmic therapy is often prescribed. The primary goals of therapy are to maintain sinus rhythm (normal heart rhythm) and to reduce the occurrence of episodes of atrial fibrillation. The double-blind, placebo-controlled phase of this study is designed to evaluate the efficacy and safety of oral azimilide compared with placebo and with sotalol, an antiarrhythmic drug, in maintaining sinus rhythm in patients who require cardioversion (electric shock to correct heart rhythm) to correct atrial fibrillation. Once this phase of the study is completed, a second phase with a different study design will be conducted. The second phase is an open-label, follow-up phase to the first study. The follow-up phase will continue to evaluate the long-term safety of a daily oral dose of azimilide in patients who complete the double-blind, placebo-controlled phase of this study.

Conditions

  • Atrial Fibrillation

Interventions

  • Azimilide DihydrochlorideDrug

    125 mg azimilide tablets, twice a day for 6 months

  • PlaceboDrug

    tablets, twice daily for 6 months

  • SotalolDrug

    160 mg sot twice daily for 6 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To prolong the time to first symptomatic or asymptomatic AFIB, etc eventTime frame: 6 month

Locations

129 sites in 9 countries. Site status is shown where the registry gives one.

  • Clinique Generale Saint Jean Service de cardiologie

    Brussels, Belgium

  • Hospital Universitarie Erasme

    Brussels, Belgium

  • Cliniques Univeristaires UCL Mont-Godinne Avenue Theresse 1

    Yvoir, Belgium

  • Service de Cardilolgie CH du Pays d'Aix

    Aix-en-Provence, France

  • CHR Besancon Service de cardiologie

    Besançon, France

  • Hopital Gavriel Montpied Cardiologie-Maladie cardiovascularies

    Clermont-Ferrand, France

  • Service de Cardiologie CHRU

    Grenoble, France

  • Cardiologie Hopital Jean Rostand

    Ivry-sur-Seine, France

  • Service de Cardiologie A Hopital Cardiologique

    Lille, France

  • Service de Cardiologie Hopital Saint Philibert

    Lomme, France

  • Cardilolgie Hopital Guillaume et Rene Laennec

    Nantes, France

  • Service de Cardiologie Hopital Lariboisiere

    Paris, France

  • Service de Cardiologie et Maladies Vascularies CHRU Pontchaillou

    Rennes, France

  • Cardiologie CHRU St Etienne/Hopital Nord

    Saint-Etienne, France

  • Centre Hospitalier General Hospital De Girac

    Saint-Michel-sur-Orge, France

  • Cardiologie/Pavillon Baudot Centre Hospitalier Universitaire Purpan

    Toulouse, France

  • Cardiologie A CHU Rangueil

    Toulouse, France

  • Service de cardiologie Hopitaux de Brabois/CHRU Nancy

    Vandœuvre-lès-Nancy, France

  • Erzgebirgskrankenhaus Klinik fur Innere Medizin

    Annaberg, Germany

  • Kerckhhoff-Klinik Abteilung Klinische Pharmakologie

    Bad Nauheim, Germany

  • Kardiologie Herzzentrum Osnabruck

    Bad Rothenfelde, Germany

  • Dr. Schreiber Krankenhaus Neukoelin 1 Innere Rudowerstrasse, 48

    Berlin, Germany

  • Franz-Volhard-Klinik Abteilung fur Elektrophysiologie

    Berlin, Germany

  • Stadisches Klinikum Brandenburg Med-Klinik I/Kardiologie Pulmologie und Angiologie

    Brandenburg, Germany

  • Klinikum Coburg II Med. Klinik

    Coburg, Germany

  • Klinkum Lippe-Detmold Med. Klink II-Kardiologie

    Detmold, Germany

  • Krankenhaus Duren Medizinische Klinik I Kardiologie/Angiologie

    Düren, Germany

  • Klinikum Erfurt GmbH

    Erfurt, Germany

  • Medizinische Universitaetsklinik Innere Medizin III Kardiologie und Angiologie

    Frieburg, Germany

  • Universitatsklinikum Hamburg-Eppendork Klinik und Poliklinik fur Innere Medizin Abteilung Kardiologie

    Hamburg, Germany

  • Medizinische Hochschule Innere Medizin/Abt. fur Kardiologie

    Hanover, Germany

  • Universitatsklinikum Heidelberg

    Heidelberg, Germany

  • Medizinische Universitats-und Ploiklinik Innere Medizin 3

    Homburg, Germany

  • Klinikum Kassel Medizinische Klinik II

    Kassel, Germany

  • Universitate zu Koeln Klinik III fur Innere Medizin

    Koeln (Lindenthal), Germany

  • Universitat Leipzig Medizinische Klinik und Poliklinik 1 Abteilung fur Kardiologie and Angiolgie

    Leipzig, Germany

  • Klinikum der Stadt Ludwigshafen Abteilung fur Elektrophysiologie der Kardiologie/Herzzentrum

    Ludwigshafen, Germany

  • Medizinische Klinik und Poliklnik Innere Medizin C

    Mannheim, Germany

  • Medizinische Klinik und Poliklinik Innere Medizin C

    Münster, Germany

  • Klinik am See REHA-Zentrum fur Herz und Kreislauf

    Rüdersdorf, Germany

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.